skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Mega Mergers

When it comes to M&A, Informa Pharma Insights has got it covered. Our readers benefit from exclusive executive interviews with industry leaders and expert analysts on business, pipeline and M&A strategy, broad and detailed coverage on implications of deal-making from antitrust to quality compliance, commercial and R&D infrastructure, regional repercussions and the impact on existing partners. 2019 has already been notable for major deals, from the closing of the $62bn Takeda/Shire acquisition to the agreed purchases of Celgene for $74bn by Bristol-Myers Squibb and of Allergan for $63bn by AbbVie, to Pfizer’s plan to merge its Upjohn generics business with Mylan. 

Click and drag the timelines below for each of the mega mergers

 1) Pfizer’s Upjohn/Mylan

Key Facts:

  • Deal announced on 29th of July 2019
  • Deal not yet completed 
  • Expected to close mid-2020

2) AbbVie's acquisition of Allergan (deal value $63bn)

Key Facts:

  • Deal announced 25 June 2019
  • Deal Not yet completed
  • Expected to close early 2020

3) Bristol-Myers Squibb’s acquisition of Celgene (deal value $74bn)

Key Facts:

  • Deal announced on 3rd of January 2019
  • Deal not yet completed
  • Expected to be late 2019 or early 2020


4) Takeda's acquisition of Shire (deal value $62bn)

Key Facts:

  • Rumours confirmed on 19 April 2018
  • Deal announced on 8 May 2018
  • Deal completed 7th  January 2019







電話:+81 (0)3 6273 4260